Aurora Counters Curaleaf's ATM Halt Bid, Intensifying Hostile Takeover Defense
ACB sits 48% above its 52-week low of $2.56.
Summary
Aurora Cannabis responded to Curaleaf's application to halt its ATM program, calling it a distraction from the inadequate hostile bid. The company highlighted Curaleaf's $1B+ debt load and revealed its own regulatory complaint with the Alberta Securities Commission.
Key Events · M&A and Partnerships · ACB
-
Curaleaf Seeks to Halt Aurora's ATM Program
Curaleaf filed an application to halt Aurora's at-the-market equity program, which Aurora says was publicly disclosed in February 2026 and has been inactive for several weeks.
-
Aurora Attacks Curaleaf's Balance Sheet
Aurora highlighted Curaleaf's more than $1 billion of debt, including $500 million senior secured notes at 11.5% interest, arguing shareholders would exchange a debt-free company for one with significant leverage.
-
Regulatory Complaint Filed with Alberta Securities Commission
Aurora raised its own complaint with the Alberta Securities Commission on September 2, 2026 about deficiencies in Curaleaf's hostile bid, which Curaleaf has not addressed.
-
Board Reaffirms Unanimous Rejection Recommendation
Aurora's Special Committee and Board unanimously recommend shareholders reject Curaleaf's US$4.00 per share bid by taking no action and not tendering shares, and to withdraw any shares already tendered.
Analysis · ACB · Life Sciences
The hostile takeover battle intensifies as Aurora Cannabis opens a new front against Curaleaf. Curaleaf has filed an application to halt Aurora's at-the-market equity program, prompting Aurora to attack Curaleaf's balance sheet—highlighting more than $1 billion in debt, including $500 million in senior secured notes at 11.5% interest. Aurora also revealed it has filed its own complaint with the Alberta Securities Commission about deficiencies in Curaleaf's bid. This is a material escalation, as Aurora seeks to convince shareholders that Curaleaf's US$4.00 per share offer undervalues the company and that Curaleaf's own financial position makes its stock an unattractive consideration.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1179 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $247M. The 52-week trading range was $2.56 to $6.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.